A team of scientists from UCLA, Stanford Medicine, the University of Utah, and Columbia University has engineered a new class of ‘supercharged’ T-cells, marking a major step toward more effective and safer immunotherapies for prostate cancer and potentially other solid tumors. Their approach, published in the March 19, 2026 edition of Science, harnesses the natural mechanics of immune cell activation to create T cells that are stronger, longer-lasting, and far more precise in targeting and killing cancer cells—without damaging healthy tissue.[1]
The Immunotherapy Challenge
Immunotherapies that use T-cells—such as CAR T-cell therapy—have revolutionized the treatment of certain blood cancers. However, their success in solid tumors like prostate cancer has been limited. A major reason is central immune tolerance: because most tumor-associated antigens (TAAs) are normal ‘self’ molecules, the immune system naturally eliminates the most powerful T-cells against them during development. This leaves behind weaker T-cells that struggle to recognize and attack tumors, especially as cancers evolve to evade immune detection.
Prostatic acid phosphatase (PAP) is one such TAA—abundantly expressed in both normal prostate tissue and prostate tumors, but not elsewhere. T-cell receptor (TCR) therapies, which engineer T-cells to recognize specific antigens like PAP, hold promise for highly targeted cancer killing. Yet, achieving both potency and safety has remained a challenge: making TCRs more sensitive can risk attacking healthy tissues, while leaving them too weak limits their effectiveness.
Engineering the ‘Catch Bond’
Instead of simply boosting the binding strength of TCRs—a method that can cause off-target toxicity—the research team introduced a natural ‘catch bond’ into the TCRs. A catch bond is a fishhook-like molecular interaction that actually gets stronger when the cell pulls against its target, as happens during an immune attack.
How it works:
- In the body, T-cells form brief, mechanical bonds with their targets. These bonds, called catch bonds, increase in strength when T-cells engage and pull on cancer cells.
- By introducing a single amino acid change in the T-cell receptor (TCR), the team created a ‘hotspot’ for catch bond formation.
- This modification allows T-cells to latch onto tumor cells more effectively at the moment of attack, extending the contact time, boosting their killing power, and maintaining exquisite specificity for cancer cells over healthy tissue.
“By engineering catch bonds, we aim to benefit more patients by overcoming immune tolerance,” said Owen N. Witte, MD, co-senior author and Presidential Chair in Developmental Immunology at UCLA Health.
Fine-Tuning the Immune Response
The scientists started with a naturally occurring, but weak, PAP-specific TCR (TCR156) from human blood. Using a novel ‘TCR turbocharging’ pipeline, they systematically scanned and mutated specific regions (complementarity-determining regions, or CDRs) of the TCR to find catch-bond “hotspots”—places where a single amino acid change could enhance the T-cell’s ability to form catch bonds with cancer cells.
Key steps included:
- Positional Scanning and Mutation: They substituted various amino acids at each position in the TCR’s CDRs, particularly focusing on those that could form hydrogen bonds or participate in strong molecular interactions.
- Gene Shuffling and Saturation Mutagenesis: By combining different mutations and testing all possibilities at key positions, they identified the most potent variants.
- Screening for Potency Without Loss of Specificity: Only those TCRs that enhanced tumor killing without increasing affinity for non-cancerous targets were advanced.
The steps resulted in two potent TCR variants (S32Mα and S30E32Qα) that kept their physiological binding affinity (important for safety) but dramatically increased the bond lifetime with the PAP antigen under mechanical force, making the T-cells much more effective at killing prostate cancer cells.
Potency and Precision
In vitro (lab) studies:
- Turbocharged T-cells showed significantly longer contact with prostate cancer cells, released more tumor-killing molecules (Granzyme B, IFNγ, TNFα), and proliferated more robustly.
- The engineered T-cells resisted exhaustion—a common problem where T-cells lose their effectiveness after prolonged engagement with tumors.
In vivo (mouse) models:
- Mice with human prostate tumors treated with the engineered T-cells experienced delayed or even halted tumor growth.
- Control mice given unmodified T-cells showed little to no tumor control.
- The engineered T-cells persisted longer inside tumors, maintained a stem-like state (enabling further expansion), and resisted entering dysfunctional or exhausted states.
Importantly, advanced imaging, single-cell RNA sequencing, and structural analyses confirmed that these modifications did not cause the T-cells to attack healthy tissue—a critical safety consideration.
How Catch Bond Engineering Works
Structural studies using X-ray crystallography and molecular modeling revealed:
- The single amino acid mutations didn’t alter the overall shape of the TCR, but ‘primed’ it to form new, dynamic interactions with the prostate cancer antigen only during immune engagement.
- These new interactions (sometimes mediated by reorganized water molecules at the interface) extend the bond duration with the tumor target under force, but do not increase binding to other, non-cancerous proteins.
Computer simulations showed that these mutations created a dynamic ‘network’ of molecular interactions that only come into play when the T-cell is actively engaging a cancer cell—explaining why the engineered T-cells are both potent and precise.
Safer, More Effective T-Cell Therapies
Traditional TCR engineering methods that simply increase affinity can inadvertently make T-cells attack healthy tissues, sometimes resulting in severe toxicity or even patient deaths in clinical trials. By contrast, catch bond engineering enhances T-cell function only during the act of killing a cancer cell, while leaving their off-target behavior unchanged.
“The strength and lifetime of the TCR’s bond with the cancer antigen under force were better predictors of tumor-killing ability than standard binding affinity,” said K. Christopher Garcia, Ph.D., co-senior author and professor at Stanford Medicine.
This approach also offers a new way to screen and select the most promising T-cell therapies: by measuring how long T-cells bind to their targets under force, researchers can more accurately predict which engineered cells will be most effective in patients.
A Generalizable Strategy
While the study focused on prostate cancer and the PAP antigen, the catch bond engineering pipeline is generalizable. It can be applied to other weak TCRs targeting different tumor-associated antigens, including those on other solid tumors where immune tolerance has historically limited the success of T cell therapies.
“By creating T-cells that are stronger, longer-lasting, and highly precise, the approach moves the field closer to safer and more effective adoptive cell therapies for patients,” Witte noted.
Funding, Collaboration, and Future Directions
This groundbreaking research was supported by the Parker Institute for Cancer Immunotherapy, the National Institutes of Health, the Howard Hughes Medical Institute, the German Research Foundation, and the UCLA Health Jonsson Comprehensive Cancer Center. It brought together experts in immunology, structural biology, and biophysical modeling from multiple leading institutions.
While further preclinical and clinical studies are needed, this work lays the foundation for a new generation of T-cell therapies—ones that can overcome the body’s natural immune brakes, home in on cancer with laser-like precision, and avoid the devastating side effects that have limited previous therapies.
By leveraging the natural ‘catch bond’ mechanism of T-cell activation, scientists have demonstrated a powerful, biophysically grounded strategy to transform weakly reactive, tolerized T-cells into potent cancer killers. This advance not only opens new therapeutic options for prostate cancer but may help unlock the potential of T-cell immunotherapy for a wide range of solid tumors—bringing hope for safer and more effective treatments to patients worldwide.
Reference
[1] Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu S, Yang A, Obenaus M, Wang N, Noguchi M, Stoyanova T, Lee JK, Good Z, Latorraca NR, Evavold BD, Witte ON, Garcia KC. Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. Science. 2026 Mar 19;391(6791):eadx3162. doi: 10.1126/science.adx3162. Epub 2026 Mar 19. PMID: 41855322; PMCID: PMC13004167.
Featured image © 2016 – 2026. Fotolia/Adome. Used with permission
DOI 10.14229/onco.2026.30.03.001
